



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

ARMOUR et al.

Atty. Ref.: 620-117

Serial No. 09/674,857

Group: 1644

Filed: November 7, 2000

Examiner: Huynh, P.

For: BINDING MOLECULES DERIVED FROM  
IMMUNOGLOBULINS WHICH DO NOT TRIGGER  
COMPLEMENT MEDIATED LYSIS

\* \* \* \* \*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

January 26, 2004

Sir:

**INFORMATION DISCLOSURE STATEMENT**

1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**  
[within 3 months of filing or prior to 1st Office Action on the merits] **N/C**

2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)] **N/C**

2 .(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)] **\$180.00**

3. **Pursuant to 37 CFR 1.97(d)**  
[after Final Office Action or Allowance (requires Rule 97(e)  
Statement and Rule 17(p) fee), but before final fee payment] **\$180.00**

The following are submitted in the above-identified application in compliance with  
37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 together with copies of each


identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
  - a) The required Statement made in item 8 below; or
  - b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
  - a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
  - b) The required Statement is stated in item 8 below.
- 8. Statement under 37 CFR 1.97(e)
  - a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
  - b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By: \_\_\_\_\_

  
B. J. Sadoff  
Reg. No. 36,663

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

<b>INFORMATION DISCLOSURE</b>		ATTY. DOCKET NO.	SERIAL NO.
<b>CITATION</b>		620-117	09/674,857
APPLICANT			
ARMOUR et al.			
(Use several sheets if necessary)		FILING DATE	GROUP
		November 7, 2000	1644

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,194,551	2/2001	Idusogie et al			

**FOREIGN PATENT DOCUMENTS**

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
99/51642	10/1999	WO				

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Duncan and Winter (1988. Nature, 332: 738 – 740)
	Valim and Lachmann (1991. Clin Exp Immunol, 84: 1 – 8)
	Sarmay et al. (1992. Mol Immunol, 29: 633 – 639)
	Michaelsen et al. (1992. Mol Immunol, 29: 319 – 326 )
	Dorai et al. (1992. Mol Immunol, 29: 1487 – 1491)
	Wright and Morrison (1994. J Exp Med, 180: 1087 – 1096 )
	Brekke et al. (1995, Immunol Today, 16: 85 – 90 )
	Ward and Ghetie (1995. Therapeutic Immunology, 2: 77 – 94)

\*Examiner \_\_\_\_\_ Date Considered \_\_\_\_\_

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)